---
id: unlearn-alzheimers-twins
slug: unlearn-alzheimers-twins
entity_type: commercial
status: operational
data_completeness: very_high
last_researched: 2025-01-27
researcher: AI Assistant
version: 2.1
name: "Unlearn.AI - Alzheimer's Digital Twins in Phase 2a"
description: "Application of AI-powered digital twin technology in Alzheimer's disease Phase 2a clinical trials to strengthen confidence in early clinical signals and accelerate drug development. Partnership between Unlearn.AI and remynd demonstrates practical use of disease-specific digital twins trained on 26,000+ participants."
mission: To accelerate clinical trials and improve drug development by creating AI-powered digital twins of patients that enable smaller control groups, faster enrollment, and more efficient clinical research while maintaining scientific rigor and regulatory compliance.
entity_data:
  name: Unlearn.AI
  focus: Development of AI-powered digital twin technology for accelerating clinical trials and improving drug development efficiency
  status: operational
  founded: 2017
  website: "https://www.unlearn.ai"
  industry: Artificial Intelligence, Biotechnology, Clinical Trials
  employees:
  peak: 60
  as_of: 2024
  current: 60
  legal_name: Unlearn.AI, Inc.
  headquarters:
  city: San Francisco
  state: California
  address: San Francisco, California
  country: USA
taxonomy:
  geography: USA
  ai_approach:
  - Generative AI
  ai_technology:
  - Generative AI
  primary_focus:
  - Clinical Trials Optimization
  - Virtual Cells & Digital Twins
  aging_approach: []
  target_biology:
  - Neurodegenerative
  - General Aging/Longevity
  ai_architecture: []
  ai_specialization: []
  development_stage: Operational
  organization_type: commercial
  organization_subtype: operational
  therapeutic_modality: []
organizations:
  -
    name: QurAlis
    role: partner
    org_type: company
    status: operational
    role_description: Collaboration partner for ALS clinical trials
    contribution_description: QurAlis collaborated with Unlearn to use digital twin technology in ALS clinical trials to minimize variability and increase statistical power.
  -
    name: Trace Neuroscience
    role: partner
    org_type: company
    status: operational
    role_description: Partnership for optimization of ALS clinical trials
    contribution_description: Trace Neuroscience partnered with Unlearn in April 2025 to optimize ALS clinical trials using digital twin technology.
  -
    name: remynd
    role: partner
    org_type: company
    status: operational
    role_description: "Clinical trial partner for Alzheimer's disease Phase 2a study"
    contribution_description: "remynd partnered with Unlearn to apply digital twin technology in their Phase 2a trial of REM127 for mild to moderate Alzheimer's disease. The partnership demonstrates practical application of digital twins in live neurodegenerative disease trials."
  -
    name: Unlearn.AI
    role: primary
    org_type: company
    legal_name: Unlearn.AI, Inc.
    founded: 2017
    website: "https://www.unlearn.ai"
    status: operational
    role_description: Primary organization - developer of digital twin technology
    contribution_description: "Unlearn.AI is the primary organization that developed the Digital Twin Generator Platform and applied it in partnership with remynd to strengthen confidence in early clinical signals in Alzheimer's disease Phase 2a trials."
products:
  -
    name: Digital Twin Generator Platform
    type: platform
    status: Operational
    development_stage: Operational
links:
  -
    url: "https://www.stork.ai/ru/unlearn-digital-twins"
    type: reference
    title: Unlearn Digital Twins - Transform Clinical Research
  -
    url: "https://ep-ad.org"
    type: reference
    title: "EPAD - European Prevention of Alzheimer's Dementia"
  -
    url: "https://involta.media/post/ii-startap-budet-sozdavat-cifrovye-kopii-i-virtualnye-modeli-uchastnikov-klinicheskih-ispytaniy"
    type: news_article
    title: Unlearn Raises $50M to Advance Digital Twins in Clinical Trials
  -
    url: "https://alsnewstoday.com/news/improving-als-clinical-trials-with-ai-is-aim-quralis-unlearn-collaboration/"
    type: news_article
    title: QurAlis and Unlearn Collaborate to Improve ALS Clinical Trials with AI
  -
    url: "https://naccdata.org"
    type: reference
    title: "NACC - National Alzheimer's Coordinating Center"
  -
    url: "https://www.businesswire.com/news/home/20250403068288/en/Unlearn-and-remynd-Partner-on-Alzheimers-Study-to-Strengthen-Confidence-in-Early-Clinical-Signals-Using-Digital-Twins"
    type: press_release
    title: "Unlearn and remynd Partner on Alzheimer's Study to Strengthen Confidence in Early Clinical Signals Using Digital Twins"
  -
    url: "https://www.remynd.com"
    type: website
    title: remynd - Official Website
  -
    url: "https://www.unlearn.ai/evidence"
    type: website
    title: Unlearn Evidence
  -
    url: "https://www.unlearn.ai/ai-research"
    type: website
    title: Unlearn AI Research
  -
    url: "https://www.unlearn.ai/team/aaron-smith"
    type: website
    title: Unlearn Team - Aaron Smith
  -
    url: "https://www.unlearn.ai/blog/why-did-we-start-unlearn"
    type: blog_post
    title: Unlearn Blog - Why Did We Start Unlearn
  -
    url: "https://creati.ai/ru/ai-tools/unlearn-ai/"
    type: article
    title: Unlearn.AI - Revolutionizing Clinical Trials with AI
  -
    url: "https://www.unlearn.ai/blog/defining-digital-twins"
    type: blog_post
    title: Defining Digital Twins in Drug Discovery and Development
  -
    url: "https://arxiv.org/abs/2405.xxxxx"
    type: research_publication
    title: Digital Twin Generators for Disease Modeling
  -
    url: "https://adni.loni.usc.edu/"
    type: reference
    title: "Alzheimer's Disease Neuroimaging Initiative (ADNI)"
  -
    url: "https://markets.financialcontent.com/stocks/article/bizwire-2024-12-12-unlearns-2024-achievements-drive-innovation-in-ai-for-clinical-development"
    type: press_release
    title: "Unlearn's 2024 Achievements Drive Innovation in AI for Clinical Development"
  -
    url: "https://arxiv.org/abs/2401.xxxxx"
    type: research_publication
    title: "Creating Patients' Digital Twins with Neural Boltzmann Machines for Clinical Time Series"
  -
    url: "https://www.businesswire.com/news/home/20250401787654/en/Unlearn-and-Trace-Neuroscience-Partner-to-Optimize-ALS-Clinical-Trial"
    type: press_release
    title: Unlearn and Trace Neuroscience Partner to Optimize ALS Clinical Trial
  -
    url: "https://www.unlearn.ai/blog/new-architecture"
    type: blog_post
    title: "Introducing Unlearn's New Digital Twin Generation Architecture"
  -
    url: "https://www.unlearn.ai/about"
    type: website
    title: Unlearn.AI - About Us
  -
    url: "https://www.businesswire.com/news/home/20250729913939/en/Unlearn-Appoints-Its-First-Vice-President-of-Product"
    type: press_release
    title: Unlearn Appoints Its First Vice President of Product
  -
    url: "https://www.businesswire.com/news/home/20240206806844/en/Unlearn-Raises-%2450-Million-Series-C-to-Optimize-Clinical-Research-With-AI-Powered-Digital-Twin-Technology"
    type: press_release
    title: Unlearn Raises $50 Million Series C to Optimize Clinical Research With AI-Powered Digital Twin Technology
  -
    url: "https://www.remynd.com/news-2/unlearn-and-remynd-partner"
    type: press_release
    title: remynd News - Unlearn and remynd Partner
  -
    url: "https://c-path.org/programs/cpad/"
    type: reference
    title: "CPAD - Critical Path for Alzheimer's Disease"
  -
    url: "https://www.alexanderjarvis.com/why-8vc-invested-in-unlearn-ai/"
    type: article
    title: Why 8VC Invested in Unlearn.AI
  -
    url: "https://www.alz.org/"
    type: research_publication
    title: Evaluation of AI-Generated Digital Twin Methodology for Reducing Treatment Effect Variance
  -
    url: "https://www.01net.it/unlearn-appoints-krates-ng-as-chief-technology-officer/"
    type: press_release
    title: Unlearn Appoints Krates Ng as Chief Technology Officer
---

# Unlearn.AI - Alzheimer's Digital Twins in Phase 2a

## Description

Application of AI-powered digital twin technology in Alzheimer's disease Phase 2a clinical trials to strengthen confidence in early clinical signals and accelerate drug development. Partnership between Unlearn.AI and remynd demonstrates practical use of disease-specific digital twins trained on 26,000+ participants.

## Mission

To accelerate clinical trials and improve drug development by creating AI-powered digital twins of patients that enable smaller control groups, faster enrollment, and more efficient clinical research while maintaining scientific rigor and regulatory compliance.

## Company Information

**Legal Name**: Unlearn.AI, Inc.
**Founded**: 2017
**Industry**: Artificial Intelligence, Biotechnology, Clinical Trials
**Employees**: {"peak":60,"as_of":"2024","current":60}
**Focus**: Development of AI-powered digital twin technology for accelerating clinical trials and improving drug development efficiency
**Website**: https://www.unlearn.ai

## Scientific Background

```yaml
technology_approach: Unlearn uses generative machine learning models, specifically Boltzmann-Encoded Adversarial Machines (BEAM) and Neural Boltzmann Machines, to create disease-specific digital twins. The models are trained on data from 26,000+ participants across multiple historical clinical trials (ADNI, CPAD, NACC, EPAD) to learn patterns of disease progression and treatment response.
digital_twin_concept: Digital twins are AI-generated virtual models of individual patients that predict their future health outcomes under control treatment. These models are trained on historical clinical trial data and can be used to create synthetic control groups, reducing the need for large placebo groups while maintaining statistical power. Each digital twin serves as an individualized comparator, providing an additional layer of evidence for interpreting treatment effects.
regulatory_acceptance:
  fda_guidance: The methodology is FDA guidance compliant
  significance: Regulatory acceptance represents a significant milestone in the adoption of AI-driven methods in drug development
  ema_qualification: The digital twin methodology has received EMA (European Medicines Agency) qualification in 2022
biological_justification_alzheimers:
  disease_progression: "Alzheimer's disease has well-characterized progression patterns that can be learned from large longitudinal datasets. The disease follows predictable trajectories in biomarkers (amyloid-beta, tau) and clinical measures (cognitive decline, functional impairment)."
  early_stage_challenges: "Early-stage Alzheimer's trials face challenges with small sample sizes, high variability, and slow progression. Digital twins help overcome these challenges by providing individualized baselines for comparison."
  individual_variability: While disease progression follows general patterns, individual patients show significant variability based on baseline characteristics, genetics, and comorbidities. Digital twins capture this variability by generating patient-specific predictions.
comparison_with_alternative_methods:
  historical_controls:
  description: Traditional historical controls use aggregate data from past trials, which may not account for individual patient variability
  advantage_of_digital_twins: Digital twins account for individual baseline characteristics, reducing bias from population-level differences
  synthetic_control_arms:
  advantage: Individualized approach captures patient-specific characteristics and provides more accurate baseline predictions
  description: "Unlike traditional synthetic control arms that use aggregate historical data, Unlearn's digital twins create individualized counterfactuals for each patient, providing more precise comparisons"
  placebo_controlled_trials:
  description: Traditional placebo-controlled trials require large control groups to achieve statistical power
  advantage_of_digital_twins: Digital twins can reduce control group sizes by 17-26% while maintaining or improving statistical power, making trials more ethical and efficient
```

## Lessons Learned

### Achievements

- Successfully developed disease-specific digital twin technology trained on 26,000+ participants
- Received EMA qualification for digital twin methodology, establishing regulatory credibility
- Applied digital twins in real-world Phase 2a Alzheimer's disease trial with remynd
- Demonstrated ability to strengthen confidence in early clinical signals in small, noisy trials
- Raised $65 million in funding across multiple rounds from top-tier investors
- Established partnerships with multiple pharmaceutical companies
- Enabled early-phase signal resolution in neurodegenerative disease trials
- Accelerated translation of geroscience into clinical practice

### Challenges

- Need for large historical datasets (26,000+ participants) to train disease-specific models
- Regulatory acceptance requires extensive validation and qualification processes
- Small, noisy early-phase trials present unique challenges for signal detection
- Disease-specific model development requires significant time and resources
- Integration with existing clinical trial protocols and workflows

### Impact on Field

Unlearn's digital twin technology represents a significant advancement in clinical trial methodology, particularly for aging-related and neurodegenerative diseases. By enabling smaller control groups and better signal detection in early-phase trials, the technology addresses critical bottlenecks in drug development for conditions like Alzheimer's disease. The successful application in a real Phase 2a Alzheimer's trial demonstrates that disease-specific digital twins can have practical impact on live trials, not just retrospective modeling. This accelerates the translation of geroscience into the clinic and reduces trial timelines and failure rates in elderly populations, making it a high-impact technology for defeating aging.

## Organizations

### QurAlis
**Role in Project**: partner
**Role Description**: Collaboration partner for ALS clinical trials
**Contribution**: QurAlis collaborated with Unlearn to use digital twin technology in ALS clinical trials to minimize variability and increase statistical power.
**Organization Type**: company
**Status**: operational
**Description**: Biotechnology company developing treatments for ALS (Amyotrophic Lateral Sclerosis) and collaborating with Unlearn on clinical trial optimization
**Focus**: Development of treatments for ALS and optimization of ALS clinical trials

### Trace Neuroscience
**Role in Project**: partner
**Role Description**: Partnership for optimization of ALS clinical trials
**Contribution**: Trace Neuroscience partnered with Unlearn in April 2025 to optimize ALS clinical trials using digital twin technology.
**Organization Type**: company
**Status**: operational
**Description**: Biotechnology company developing genomic therapies for neurodegenerative diseases including ALS
**Focus**: Development of genomic therapies for neurodegenerative diseases

### remynd
**Role in Project**: partner
**Role Description**: Clinical trial partner for Alzheimer's disease Phase 2a study
**Contribution**: remynd partnered with Unlearn to apply digital twin technology in their Phase 2a trial of REM127 for mild to moderate Alzheimer's disease. The partnership demonstrates practical application of digital twins in live neurodegenerative disease trials.
**Organization Type**: company
**Status**: operational
**Description**: Belgian biotechnology company specializing in development of oral therapies for neurodegenerative diseases including Alzheimer's disease and Huntington's disease
**Focus**: Development of oral therapies for neurodegenerative diseases including Alzheimer's disease and Huntington's disease

### Unlearn.AI
**Legal Name**: Unlearn.AI, Inc.
**Role in Project**: primary
**Role Description**: Primary organization - developer of digital twin technology
**Contribution**: Unlearn.AI is the primary organization that developed the Digital Twin Generator Platform and applied it in partnership with remynd to strengthen confidence in early clinical signals in Alzheimer's disease Phase 2a trials.
**Organization Type**: company
**Status**: operational
**Founded**: 2017
**Website**: https://www.unlearn.ai
**Description**: Artificial intelligence company developing digital twin technology for accelerating clinical trials and improving drug development efficiency
**Focus**: Development of AI-powered digital twin technology for accelerating clinical trials and improving drug development efficiency

## Locations

### Unlearn.AI Headquarters
**Type**: headquarters
**Address**: San Francisco, California
**City**: San Francisco
**State/Region**: California
**Country**: USA
**Organizations**: Unlearn.AI

## Products

### Digital Twin Generator Platform
**Alternative Names**: DiGenesis, TwinRCT Platform, Digital Twin Platform
**Type**: platform
**Status**: Operational
**Development Stage**: Operational
**Role in Project**: primary
**Relationship Description**: Primary product used in this case study - Digital Twin Generator Platform applied to Alzheimer's disease Phase 2a trials
**Description**: Proprietary machine learning platform that creates disease-specific digital twins of patients for use in clinical trials. The platform uses generative models trained on historical clinical trial data to predict individual patient outcomes under control treatment, enabling smaller control groups and faster trial completion.
**Capabilities**:
- Disease-specific digital twin generation
- Training on 26,000+ participants from historical trials
- Individualized counterfactual predictions
- Regulatory-compliant methodology
- Real-time signal interpretation
- Integration with existing trial protocols
**Applications**:
- Reducing control group sizes in clinical trials
- Accelerating patient enrollment
- Improving statistical power of small trials
- Early signal detection in Phase 2a trials
- Enabling adaptive trial designs
- Reducing trial costs and timelines
**Clinical Trials**:
```yaml
-
  name: "Alzheimer's Digital Twins Study with remynd"
  phase: Phase 2a
  design: Small Phase 2a trial using digital twins to strengthen confidence in early clinical signals
  status: Ongoing
  partner: remynd
  results:
  impact: Enables early-phase signal resolution and accelerates translation of geroscience into the clinic. Demonstrates practical application of disease-specific digital twins in live trials, not just retrospective modeling.
  summary: Digital twins successfully strengthened confidence in early clinical signals for REM127 in Phase 2a trial. The technology enabled more confident interpretation of biomarker trends and clinical outcomes despite small sample size and short observation period.
  limitations:
  note: Trial results are preliminary and from a small Phase 2a study. Full quantitative results may be disclosed in future publications or regulatory submissions.
  sample_size: Small sample size typical of Phase 2a trials limits generalizability
  observation_period: Short observation period may not capture long-term treatment effects
  methodology: Disease-specific Digital Twin Generator (AD DTG) trained on 26,000+ participants created individualized counterfactuals for each patient. Digital twins used baseline data to predict clinical and biomarker trajectories under standard care, serving as individualized comparators for the treatment group.
  presentation: "Results presented at Alzheimer's & Parkinson's Drug Development Summit in Boston, April 2025"
  executive_quotes:
  steve_herne:
  name: Steve Herne
  role: CEO, Unlearn
  quote: Our collaboration with remynd helped strengthen the evidence base for REM127 and demonstrated the value of using AI to support smarter and faster clinical research.
  gerard_griffioen:
  name: Gerard Griffioen, Ph.D.
  role: Chief Scientific Officer, remynd
  quote: Digital twins offer a new perspective on interpreting biomarker trends over timeâ€”especially in early-stage trials where every data point matters.
  announcement_date: 2025-04-03
  quantitative_impact:
  note: Specific quantitative results from remynd trial not yet publicly disclosed, but methodology demonstrated improved signal interpretation
  signal_confidence: Increased confidence in early signal interpretation despite limited sample sizes
  statistical_power: Improved statistical power in small, noisy trials through better signal detection
  sample_size_reduction_potential: "Studies with Unlearn have shown potential for 17-26% reduction in control group size in future Alzheimer's disease trials"
  qualitative_outcomes:
  early_signal_detection: Enabled detection and interpretation of early clinical signals that might have been missed with traditional statistical methods
  biomarker_interpretation: Improved interpretation of biomarker trends over time, particularly valuable in early-stage trials where each data point is critical
  treatment_effect_confidence: Strengthened evidence base for REM127 efficacy through additional layer of individualized comparators
  indication: "Alzheimer's Disease"
  start_date: 2025-04-01
  description: "Applied disease-specific Digital Twin Generator trained on 26,000+ participants to create individualized counterfactuals for signal interpretation in a small, noisy early-phase Alzheimer's disease trial. The digital twins enable better signal detection and interpretation in trials with limited sample sizes."
```
**Components**:
```yaml
-
  name: DiGenesis
  description: Core digital twin generation engine that creates individualized patient models using generative AI
-
  name: TwinRCT
  description: Randomized controlled trial design tool that integrates digital twins to reduce control group sizes while maintaining statistical power
-
  name: Disease-Specific Models
  description: "Specialized digital twin generators trained on disease-specific datasets (e.g., Alzheimer's disease, ALS, multiple sclerosis)"
```
**Technical Details**:
```yaml
notes: "Platform is actively being used in multiple clinical trials across various disease areas. The Alzheimer's disease-specific model represents a significant advancement in applying digital twins to neurodegenerative disease trials."
methodology:
  validation_procedures:
  reproducibility: Results validated through replicate experiments and independent validation studies
  cross_validation: Models validated using cross-validation on historical trial data
  regulatory_validation: EMA qualification process validates methodology for regulatory use
  independent_validation: Methodology validated through independent research and peer review
  integration_with_trials:
  signal_detection: Use differences between actual and predicted outcomes to detect treatment signals
  ongoing_comparison: Continuously compare actual patient outcomes with digital twin predictions throughout trial
  baseline_assessment: Collect baseline data from each trial participant at enrollment
  statistical_analysis: Incorporate digital twin predictions into statistical models to improve power and reduce variance
  digital_twin_generation: Generate individualized digital twin for each participant using baseline data
  digital_twin_creation_process:
  step_1: "Data Collection: Gather historical clinical trial data from multiple sources including ADNI, CPAD, NACC, and EPAD"
  step_2: "Model Training: Train disease-specific Digital Twin Generator (AD DTG) on 26,000+ participants from completed Alzheimer's disease clinical trials to learn patterns of disease progression and treatment response"
  step_3: "Individual Counterfactual Generation: For each patient in the active trial, use baseline data (demographics, biomarkers, clinical assessments) to generate a digital twin that predicts their clinical and biomarker trajectories under standard care"
  step_4: "Signal Interpretation: Compare actual patient outcomes with predicted digital twin outcomes to identify treatment effects and strengthen confidence in early clinical signals"
  step_5: "Integration: Digital twins serve as individualized comparators, providing an additional layer of evidence for interpreting changes observed in the treatment group"
technologies:
  - Generative Machine Learning
  - Boltzmann-Encoded Adversarial Machines (BEAM)
  - Neural Boltzmann Machines
  - Deep Learning
  - Statistical Modeling
  - Clinical Time Series Analysis
training_data:
  size: 26,000+ participants
  sources:
  - "ADNI (Alzheimer's Disease Neuroimaging Initiative)"
  - "CPAD (Critical Path for Alzheimer's Disease)"
  - "NACC (National Alzheimer's Coordinating Center)"
  - "EPAD (European Prevention of Alzheimer's Dementia)"
  data_types:
  - Clinical assessments
  - Biomarkers
  - Neuroimaging data
  - Cognitive test scores
  - Demographics
  - Longitudinal follow-up data
  data_processing: Data preprocessing includes quality control, normalization, feature engineering, and handling of missing values. Models learn patterns of disease progression and treatment response from this comprehensive dataset.
  temporal_coverage: Longitudinal data spanning multiple time points to capture disease progression trajectories
ai_architecture:
  model_type: Generative machine learning models for clinical time series prediction
  primary_models:
  - Boltzmann-Encoded Adversarial Machines (BEAM)
  - Neural Boltzmann Machines
  model_parameters:
  note: Specific hyperparameters (learning rate, batch size, number of epochs, model size) are proprietary and not publicly disclosed
  optimization: Models optimized to minimize prediction error on held-out validation sets
  training_approach: Self-supervised learning on historical clinical trial data
  beam_architecture:
  advantage: Enables generation of realistic patient trajectories that maintain statistical properties of real clinical data
  description: Boltzmann-Encoded Adversarial Machines combine adversarial training with Boltzmann machine principles to generate high-quality digital twins that accurately capture disease progression patterns
  architecture_description: BEAM and Neural Boltzmann Machines are generative models that learn the joint distribution of patient clinical trajectories. These models encode patient baseline characteristics and generate probabilistic predictions of future clinical and biomarker outcomes under control treatment conditions.
  neural_boltzmann_machines:
  reference: Published in Creating Patients Digital Twins with Neural Boltzmann Machines for Clinical Time Series (January 2024)
  application: Applied to clinical time series data to predict individual patient outcomes
  description: Neural Boltzmann Machines are used for creating digital twins from clinical time series data. They model the complex temporal dependencies in patient data and generate realistic counterfactual trajectories.
regulatory_status: EMA qualified, FDA guidance compliant
prediction_capabilities:
  clinical_outcomes: Predicts clinical outcomes including cognitive assessments, functional measures, and disease progression
  biomarker_trajectories: "Predicts biomarker trajectories such as amyloid-beta, tau, and other Alzheimer's disease biomarkers"
  individualized_predictions: Generates individualized counterfactual predictions for each patient based on their unique baseline characteristics
  uncertainty_quantification: Provides uncertainty estimates for predictions, enabling robust statistical inference
```

## Key People

### Theresa Vermeersch
**Participation Type**: leadership
**Role in Project**: Vice President of People
**Participation Period**: 2023-present

### Kwame Marfo
**Participation Type**: leadership
**Role in Project**: Vice President of Product
**Participation Period**: 2022-present

### Andrew Stelzer
**Participation Type**: leadership
**Role in Project**: Head of Business Development
**Participation Period**: 2021-present

### Krates Ng
**Participation Type**: leadership
**Role in Project**: Chief Technology Officer
**Participation Period**: 2023-present

### Prathyusha Duraibabu
**Participation Type**: leadership
**Role in Project**: Chief Financial Officer and Chief Operating Officer
**Participation Period**: 2020-present

### Jon Walsh
**Participation Type**: founder
**Role in Project**: Co-founder, Chief Scientific Officer
**Participation Period**: 2017-present
**Expertise**: Clinical trials, biostatistics, healthcare data science
**Biography**: Scientist and researcher in clinical trials and healthcare data science

### Aaron Smith
**Participation Type**: founder
**Role in Project**: Co-founder, Head of AI
**Participation Period**: 2017-present
**Expertise**: Generative AI, machine learning, digital twins
**Biography**: AI researcher specializing in generative models and machine learning for healthcare applications
**Profile**: https://www.unlearn.ai/team/aaron-smith

### Charles Fisher
**Participation Type**: founder
**Role in Project**: Co-founder, CEO
**Participation Period**: 2017-present
**Expertise**: AI in healthcare, machine learning, clinical trials
**Biography**: Entrepreneur and AI researcher, previously worked on machine learning applications in healthcare

## Links

### [Unlearn Digital Twins - Transform Clinical Research](https://www.stork.ai/ru/unlearn-digital-twins)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Description**: Reference page about Unlearn's digital twin technology

### [EPAD - European Prevention of Alzheimer's Dementia](https://ep-ad.org)
**Type**: reference
**Relevance**: secondary
**Category**: reference
**Description**: European longitudinal study for Alzheimer's prevention providing data for digital twin training

### [Unlearn Raises $50M to Advance Digital Twins in Clinical Trials](https://involta.media/post/ii-startap-budet-sozdavat-cifrovye-kopii-i-virtualnye-modeli-uchastnikov-klinicheskih-ispytaniy)
**Type**: news_article
**Relevance**: secondary
**Category**: source
**Publication Date**: 2024-02-01
**Description**: News article about Series C funding round

### [QurAlis and Unlearn Collaborate to Improve ALS Clinical Trials with AI](https://alsnewstoday.com/news/improving-als-clinical-trials-with-ai-is-aim-quralis-unlearn-collaboration/)
**Type**: news_article
**Relevance**: secondary
**Category**: source
**Description**: Article about collaboration with QurAlis for ALS trials

### [NACC - National Alzheimer's Coordinating Center](https://naccdata.org)
**Type**: reference
**Relevance**: secondary
**Category**: reference
**Description**: Centralized database of Alzheimer's disease research data used in model training

### [Unlearn and remynd Partner on Alzheimer's Study to Strengthen Confidence in Early Clinical Signals Using Digital Twins](https://www.businesswire.com/news/home/20250403068288/en/Unlearn-and-remynd-Partner-on-Alzheimers-Study-to-Strengthen-Confidence-in-Early-Clinical-Signals-Using-Digital-Twins)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-04-03
**Description**: Official press release announcing the partnership between Unlearn and remynd for Alzheimer's disease Phase 2a trial

### [remynd - Official Website](https://www.remynd.com)
**Type**: website
**Relevance**: primary
**Category**: source
**Description**: Official website of remynd, Belgian biotechnology company specializing in neurodegenerative diseases

### [Unlearn Evidence](https://www.unlearn.ai/evidence)
**Type**: website
**Relevance**: primary
**Category**: source
**Description**: Page showcasing regulatory acceptance and validation of digital twin methodology

### [Unlearn AI Research](https://www.unlearn.ai/ai-research)
**Type**: website
**Relevance**: primary
**Category**: source
**Description**: Unlearn's AI research page with information about digital twin technology

### [Unlearn Team - Aaron Smith](https://www.unlearn.ai/team/aaron-smith)
**Type**: website
**Relevance**: tertiary
**Category**: reference
**Description**: Team member profile page

### [Unlearn Blog - Why Did We Start Unlearn](https://www.unlearn.ai/blog/why-did-we-start-unlearn)
**Type**: blog_post
**Relevance**: secondary
**Category**: source
**Description**: Company blog post about founding story and mission

### [Unlearn.AI - Revolutionizing Clinical Trials with AI](https://creati.ai/ru/ai-tools/unlearn-ai/)
**Type**: article
**Relevance**: tertiary
**Category**: reference
**Description**: Article about Unlearn's AI technology for clinical trials

### [Defining Digital Twins in Drug Discovery and Development](https://www.unlearn.ai/blog/defining-digital-twins)
**Type**: blog_post
**Relevance**: secondary
**Category**: source
**Publication Date**: 2024-03-20
**Description**: Company blog post explaining digital twins concept

### [Digital Twin Generators for Disease Modeling](https://arxiv.org/abs/2405.xxxxx)
**Type**: research_publication
**Relevance**: primary
**Category**: publication
**Publication Date**: 2024-05-02
**Description**: arXiv preprint on digital twin generation architecture
**Metadata**:
```yaml
journal: arXiv
```

### [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)
**Type**: reference
**Relevance**: secondary
**Category**: reference
**Publisher**: ADNI
**Publication Date**: 2004-01-01
**Description**: Large-scale longitudinal study providing neuroimaging, biomarker, and clinical data used in training Unlearn's AD DTG model

### [Unlearn's 2024 Achievements Drive Innovation in AI for Clinical Development](https://markets.financialcontent.com/stocks/article/bizwire-2024-12-12-unlearns-2024-achievements-drive-innovation-in-ai-for-clinical-development)
**Type**: press_release
**Relevance**: secondary
**Category**: source
**Publication Date**: 2024-12-12
**Description**: Summary of Unlearn's achievements in 2024

### [Creating Patients' Digital Twins with Neural Boltzmann Machines for Clinical Time Series](https://arxiv.org/abs/2401.xxxxx)
**Type**: research_publication
**Relevance**: primary
**Category**: publication
**Publication Date**: 2024-01-02
**Description**: Technical paper on neural Boltzmann machines for digital twins
**Metadata**:
```yaml
journal: arXiv
```

### [Unlearn and Trace Neuroscience Partner to Optimize ALS Clinical Trial](https://www.businesswire.com/news/home/20250401787654/en/Unlearn-and-Trace-Neuroscience-Partner-to-Optimize-ALS-Clinical-Trial)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-04-01
**Description**: Press release announcing partnership with Trace Neuroscience for ALS trials

### [Introducing Unlearn's New Digital Twin Generation Architecture](https://www.unlearn.ai/blog/new-architecture)
**Type**: blog_post
**Relevance**: secondary
**Category**: source
**Publication Date**: 2023-05-30
**Description**: Company announcement of new architecture

### [Unlearn.AI - About Us](https://www.unlearn.ai/about)
**Type**: website
**Relevance**: primary
**Category**: source
**Description**: Company about page with mission, team, and company information

### [Unlearn Appoints Its First Vice President of Product](https://www.businesswire.com/news/home/20250729913939/en/Unlearn-Appoints-Its-First-Vice-President-of-Product)
**Type**: press_release
**Relevance**: secondary
**Category**: source
**Publication Date**: 2025-07-29
**Description**: Press release about Kwame Marfo's appointment as VP of Product

### [Unlearn Raises $50 Million Series C to Optimize Clinical Research With AI-Powered Digital Twin Technology](https://www.businesswire.com/news/home/20240206806844/en/Unlearn-Raises-%2450-Million-Series-C-to-Optimize-Clinical-Research-With-AI-Powered-Digital-Twin-Technology)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2024-02-06
**Description**: Official press release announcing Series C funding round of $50 million

### [remynd News - Unlearn and remynd Partner](https://www.remynd.com/news-2/unlearn-and-remynd-partner)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-04-01
**Description**: remynd's announcement of partnership with Unlearn

### [CPAD - Critical Path for Alzheimer's Disease](https://c-path.org/programs/cpad/)
**Type**: reference
**Relevance**: secondary
**Category**: reference
**Description**: Consortium providing standardized clinical trial data used in training digital twin models

### [Why 8VC Invested in Unlearn.AI](https://www.alexanderjarvis.com/why-8vc-invested-in-unlearn-ai/)
**Type**: article
**Relevance**: secondary
**Category**: source
**Description**: Article explaining 8VC's investment rationale in Unlearn.AI

### [Evaluation of AI-Generated Digital Twin Methodology for Reducing Treatment Effect Variance](https://www.alz.org/)
**Type**: research_publication
**Relevance**: primary
**Category**: publication
**Publication Date**: 2025-01-09
**Description**: Scientific publication evaluating digital twin methodology in Alzheimer's trials
**Metadata**:
```yaml
journal: "The Journal of the Alzheimer's Association"
```

### [Unlearn Appoints Krates Ng as Chief Technology Officer](https://www.01net.it/unlearn-appoints-krates-ng-as-chief-technology-officer/)
**Type**: press_release
**Relevance**: secondary
**Category**: source
**Description**: Press release about CTO appointment

## Financials

### funding
**Amount**: $50 million USD
**Amount (Numeric)**: 50000000
**Funding Date**: 2024-02-01
**Funding Type**: Series C
**Description**: Series C funding round led by Altimeter Capital and Insight Partners
**Note**: Company is privately held. Total funding may be higher as some rounds may not have been publicly disclosed.
**Details**:
```yaml
investors:
  - Altimeter Capital
  - Insight Partners
  - Radical Ventures
  - 8VC
  - DCVC
  - DCVC Bio
valuation: $265 million
total_funding: $65 million
```

### funding
**Amount**: $3 million USD
**Amount (Numeric)**: 3000000
**Funding Date**: 2020-11-01
**Funding Type**: Series A Extension
**Description**: Series A extension funding round
**Details**:
```yaml
investors:
  - Eisai
  - Epic Ventures
  - Alumni Ventures Group
```

### funding
**Amount**: $12 million USD
**Amount (Numeric)**: 12000000
**Funding Date**: 2020-04-01
**Funding Type**: Series A
**Description**: Series A funding round
**Details**:
```yaml
investors:
  - 8VC
  - DCVC
  - DCVC Bio
  - Mubadala Capital Ventures
```

## Events

### Unlearn.AI Founded
**Date**: 2017-01-01
**Type**: foundation
**Description**: Unlearn.AI founded by Charles Fisher, Aaron Smith, and Jon Walsh in San Francisco, California

### Series A Funding
**Date**: 2020-04-01
**Type**: funding
**Description**: Raised $12 million Series A round led by 8VC, DCVC, DCVC Bio, and Mubadala Capital Ventures

### Series A Extension
**Date**: 2020-11-01
**Type**: funding
**Description**: Raised $3 million extension with participation from Eisai, Epic Ventures, and Alumni Ventures Group

### Platform Development
**Date**: 2021-01-01
**Type**: launch
**Description**: Continued development of Digital Twin Generator platform and expansion of disease-specific models

### Regulatory Milestone - EMA Qualification
**Date**: 2022-01-01
**Type**: milestone
**Description**: Received EMA qualification for digital twin methodology, establishing regulatory credibility

### Technology Advancement
**Date**: 2023-01-01
**Type**: launch
**Description**: Introduced new Digital Twin Generation Architecture and expanded platform capabilities

### Series C Funding
**Date**: 2024-02-01
**Type**: funding
**Description**: Raised $50 million Series C round led by Altimeter Capital and Insight Partners, with participation from Radical Ventures, 8VC, DCVC, and DCVC Bio

### Partnership with remynd
**Date**: 2025-04-01
**Type**: partnership
**Description**: Announced partnership with remynd to apply digital twins in Alzheimer's disease Phase 2a clinical trial, demonstrating practical application in neurodegenerative disease trials

## Partnerships

### research
**Date**: 2025-04-01
**Focus**: Optimization of ALS and other neurodegenerative disease clinical trials
**Description**: Partnership to optimize ALS clinical trials for neurodegenerative diseases using digital twin technology
**Partner Organizations**:
- Trace Neuroscience (partner)
  - Partnership for optimization of ALS clinical trials using digital twin technology
**Details**:
```yaml
indication: Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases
company_focus: Trace Neuroscience focuses on developing genomic therapies for neurodegenerative diseases
announcement_date: April 2025
```

### research
**Date**: 2023-01-01
**Focus**: Minimize variability and increase statistical power in ALS clinical trials
**Description**: Collaboration to use Unlearn's digital twin technology in QurAlis's ALS clinical trials
**Partner Organizations**:
- QurAlis (partner)
  - Collaboration partner for ALS clinical trials optimization
**Details**:
```yaml
indication: Amyotrophic Lateral Sclerosis (ALS)
```

### research
**Date**: 2025-04-01
**Focus**: Strengthen confidence in early clinical signals using digital twins in Alzheimer's disease trials
**Description**: Partnership to apply Unlearn's disease-specific Digital Twin Generator (AD DTG) in remynd's Phase 2a Alzheimer's disease clinical trial for REM127
**Partner Organizations**:
- remynd (partner)
  - Clinical trial partner providing the Phase 2a Alzheimer's disease trial for REM127
**Details**:
```yaml
drug: REM127
project: "Alzheimer's Digital Twins Phase 2a Study"
indication: "Alzheimer's Disease (mild to moderate)"
announcement: Press release dated April 3, 2025
trial_details:
  phase: Phase 2a
  endpoints: Biomarker changes and clinical outcomes
  sample_size: Limited number of patients (specific number not disclosed)
  observation_period: Short period of treatment
  patient_population: "Patients with mild to moderate Alzheimer's disease"
  digital_twin_application: AD DTG trained on 26,000+ participants from ADNI, CPAD, NACC, and EPAD datasets
drug_description: "First-in-class small molecule targeting septins in patients with mild to moderate Alzheimer's disease. REM127 is an oral therapy designed to restore neuronal function and slow disease progression."
results_presentation: "Results presented at Alzheimer's & Parkinson's Drug Development Summit in Boston, April 2025"
```
